Neuren gains FDA orphan status for NNZ-2591 in neonatal brain injury

FDA designation advances NNZ-2591 towards HIE testing

Neuren Pharmaceuticals (ASX:NEU) has secured a regulatory milestone for NNZ-2591, with the US Food and Drug Administration granting Orphan Drug Designation for the treatment of neonatal hypoxic-ischemic encephalopathy, or HIE.

The designation applies to a rare condition in which a baby’s brain is deprived of sufficient oxygen or blood flow before or shortly after birth. Neuren describes HIE as a major cause of neonatal death and neurodevelopmental disability, with possible long-term consequences including developmental delay, cognitive impairment, cerebral palsy and seizures.

Seven-year exclusivity is potential commercial benefit

For Neuren, the designation brings possible commercial and regulatory advantages rather than an approval to market the drug. Orphan Drug status can provide seven years of US marketing exclusivity and a waiver of prescription drug user fees for a marketing application, subject to the programme ultimately meeting the requirements for approval.

Chief executive Jon Pilcher called the designation an “important commercial milestone” and said Neuren now plans to discuss the development path with the FDA while preparing an application to begin clinical testing in HIE.

Safety study precedes planned 2027 IND submission

Neuren is currently conducting a juvenile animal safety study that it says is required by the FDA before a clinical study in HIE can begin. The company plans to submit an Investigational New Drug application in the first half of 2027, although the announcement does not provide a confirmed submission date or clinical trial design.

NNZ-2591 is also being developed for several neurodevelopmental disorders, including Phelan-McDermid syndrome, Pitt-Hopkins syndrome and Angelman syndrome. The separate Phase 3 Koala trial is evaluating NNZ-2591 in children with Phelan-McDermid syndrome, while the HIE programme remains at the preclinical safety and regulatory preparation stage.

Clinical proof in HIE remains the next test

The FDA designation does not establish that NNZ-2591 is effective in HIE, and the filing contains no human efficacy data for the condition. The immediate milestones are completion of the juvenile safety work, FDA discussions and the planned IND submission, followed by any decision to authorise clinical testing.